Recent developments in the radioimmunotherapy of cancer.
Recent trials using radiolabeled monoclonal antibodies, particularly for hematologic neoplasms, have demonstrated the ability of these agents to destroy tumor cells safely and specifically. Advances in molecular biology, immunology and radiochemistry will allow the continued development of strategies to overcome the remaining obstacles to effective therapy with radioimmunoconjugates.
Jurcic
J G
JG
Memorial Sloan-Kettering Cancer Center New York, New York.
Scheinberg
D A
DA
D000818:Animals; D006801:Humans; D007938:Leukemia / Q000532:radiotherapy; D008223:Lymphoma / Q000532:radiotherapy; D009369:Neoplasms / Q000532:radiotherapy*; D016499:Radioimmunotherapy / Q000639:trends*; D011868:Radioisotopes / Q000737:chemistry
D011868:Radioisotopes